Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Rohit K Jain, Hongbin Chen Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. Crizotinib was the...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2017-10-01
|
| Seri Bilgileri: | Lung Cancer: Targets and Therapy |
| Konular: | |
| Online Erişim: | https://www.dovepress.com/spotlight-on-brigatinib-and-its-potential-in-the-treatment-of-patients-peer-reviewed-article-LCTT |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|